At present, anti-PD-1/PD-L1 antibodies alone or in combination with anti-CTLA-4 antibodies or targeted therapies have become first-line therapies for a variety of cancers such as metastatic melanoma, lung cancer, head and neck cancer, and triple-negative breast cancer [8]. Here, CD274 is linked to cancer.